CA2890273C - A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) - Google Patents
A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) Download PDFInfo
- Publication number
- CA2890273C CA2890273C CA2890273A CA2890273A CA2890273C CA 2890273 C CA2890273 C CA 2890273C CA 2890273 A CA2890273 A CA 2890273A CA 2890273 A CA2890273 A CA 2890273A CA 2890273 C CA2890273 C CA 2890273C
- Authority
- CA
- Canada
- Prior art keywords
- hcc
- dihydro
- oxo
- treatment
- hepatocellular carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 3
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007494.3 | 2012-11-02 | ||
| EP12007494 | 2012-11-02 | ||
| PCT/EP2013/002998 WO2014067610A1 (en) | 2012-11-02 | 2013-10-04 | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2890273A1 CA2890273A1 (en) | 2014-05-08 |
| CA2890273C true CA2890273C (en) | 2021-10-26 |
Family
ID=47143496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2890273A Active CA2890273C (en) | 2012-11-02 | 2013-10-04 | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20150283137A1 (enExample) |
| EP (1) | EP2914264B1 (enExample) |
| JP (1) | JP6255028B2 (enExample) |
| KR (1) | KR102131588B1 (enExample) |
| CN (1) | CN104768553A (enExample) |
| AR (1) | AR093318A1 (enExample) |
| AU (1) | AU2013339823B2 (enExample) |
| BR (1) | BR112015008279A2 (enExample) |
| CA (1) | CA2890273C (enExample) |
| DK (1) | DK2914264T3 (enExample) |
| ES (1) | ES2646913T3 (enExample) |
| HK (1) | HK1211869A1 (enExample) |
| HR (1) | HRP20171295T1 (enExample) |
| HU (1) | HUE035483T2 (enExample) |
| IL (1) | IL238536B (enExample) |
| LT (1) | LT2914264T (enExample) |
| MX (1) | MX354518B (enExample) |
| NO (1) | NO2914264T3 (enExample) |
| PL (1) | PL2914264T3 (enExample) |
| PT (1) | PT2914264T (enExample) |
| RS (1) | RS56485B1 (enExample) |
| RU (1) | RU2650679C2 (enExample) |
| SG (1) | SG11201503214YA (enExample) |
| SI (1) | SI2914264T1 (enExample) |
| WO (1) | WO2014067610A1 (enExample) |
| ZA (1) | ZA201503924B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921310C (en) | 2013-08-14 | 2021-04-20 | Yugenkaisha Japan Tsusyo | Hydroponic cultivation system, and plant factory comprising hydroponic cultivation system and expanded polystyrene foam greenhouse |
| LT3996688T (lt) * | 2019-07-10 | 2023-12-27 | Merck Patent Gmbh | Farmacinis preparatas |
| JP2022551672A (ja) * | 2019-10-14 | 2022-12-12 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 乳癌治療法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| KR101829595B1 (ko) * | 2009-01-08 | 2018-02-14 | 메르크 파텐트 게엠베하 | 3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법 |
-
2013
- 2013-10-04 RU RU2015120692A patent/RU2650679C2/ru active
- 2013-10-04 AU AU2013339823A patent/AU2013339823B2/en active Active
- 2013-10-04 CN CN201380057293.0A patent/CN104768553A/zh active Pending
- 2013-10-04 KR KR1020157014482A patent/KR102131588B1/ko active Active
- 2013-10-04 DK DK13776720.8T patent/DK2914264T3/en active
- 2013-10-04 ES ES13776720.8T patent/ES2646913T3/es active Active
- 2013-10-04 PT PT137767208T patent/PT2914264T/pt unknown
- 2013-10-04 SG SG11201503214YA patent/SG11201503214YA/en unknown
- 2013-10-04 BR BR112015008279A patent/BR112015008279A2/pt not_active Application Discontinuation
- 2013-10-04 EP EP13776720.8A patent/EP2914264B1/en active Active
- 2013-10-04 RS RS20171129A patent/RS56485B1/sr unknown
- 2013-10-04 NO NO13776720A patent/NO2914264T3/no unknown
- 2013-10-04 LT LTEP13776720.8T patent/LT2914264T/lt unknown
- 2013-10-04 JP JP2015541023A patent/JP6255028B2/ja active Active
- 2013-10-04 WO PCT/EP2013/002998 patent/WO2014067610A1/en not_active Ceased
- 2013-10-04 HU HUE13776720A patent/HUE035483T2/hu unknown
- 2013-10-04 US US14/440,181 patent/US20150283137A1/en not_active Abandoned
- 2013-10-04 PL PL13776720T patent/PL2914264T3/pl unknown
- 2013-10-04 CA CA2890273A patent/CA2890273C/en active Active
- 2013-10-04 MX MX2015005265A patent/MX354518B/es active IP Right Grant
- 2013-10-04 HR HRP20171295TT patent/HRP20171295T1/hr unknown
- 2013-10-04 HK HK16100004.6A patent/HK1211869A1/xx unknown
- 2013-10-04 SI SI201330832T patent/SI2914264T1/sl unknown
- 2013-11-01 AR ARP130103990A patent/AR093318A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 IL IL238536A patent/IL238536B/en active IP Right Grant
- 2015-06-01 ZA ZA2015/03924A patent/ZA201503924B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2914264A1 (en) | 2015-09-09 |
| MX2015005265A (es) | 2015-07-17 |
| HRP20171295T1 (hr) | 2017-10-20 |
| HK1211869A1 (en) | 2016-06-03 |
| PT2914264T (pt) | 2017-11-14 |
| HUE035483T2 (hu) | 2018-05-02 |
| CA2890273A1 (en) | 2014-05-08 |
| SG11201503214YA (en) | 2015-05-28 |
| DK2914264T3 (en) | 2017-09-11 |
| AU2013339823A1 (en) | 2015-06-18 |
| IL238536A0 (en) | 2015-06-30 |
| US20150283137A1 (en) | 2015-10-08 |
| WO2014067610A1 (en) | 2014-05-08 |
| JP2015536957A (ja) | 2015-12-24 |
| KR102131588B1 (ko) | 2020-07-08 |
| BR112015008279A2 (pt) | 2017-07-04 |
| RU2650679C2 (ru) | 2018-04-17 |
| CN104768553A (zh) | 2015-07-08 |
| AU2013339823B2 (en) | 2018-01-04 |
| EP2914264B1 (en) | 2017-08-09 |
| PL2914264T3 (pl) | 2017-12-29 |
| KR20150079942A (ko) | 2015-07-08 |
| SI2914264T1 (sl) | 2017-12-29 |
| ES2646913T3 (es) | 2017-12-18 |
| MX354518B (es) | 2018-03-08 |
| AR093318A1 (es) | 2015-05-27 |
| NO2914264T3 (enExample) | 2018-01-06 |
| JP6255028B2 (ja) | 2017-12-27 |
| IL238536B (en) | 2019-01-31 |
| RS56485B1 (sr) | 2018-01-31 |
| RU2015120692A (ru) | 2016-12-27 |
| LT2914264T (lt) | 2017-11-10 |
| ZA201503924B (en) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2373640T3 (da) | Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf | |
| CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
| CL2007002640A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2007002642A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| PH12017500719A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| IL225704A (en) | Polymorphs and salts of 6– (1 h– indole – 4 – ram) –4– (5 - {[4– (1-methylethyl) –1 – piperazine] methyl} –1,3 – oxazole – 2 – ram) –1 h- Indazole as pi3k inhibitors for use in treating respiratory problems | |
| EP3395342A4 (en) | TABLET WITH 1- (3- (2- (1-BENZOTHIOPHEN-5-YL-) ETHOXY-) PROPYL-) AZETIDIN-3-OL OR A SALT THEREOF | |
| CA2890273C (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) | |
| PH12017500718A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor | |
| PH12016500948A1 (en) | Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib | |
| SI3408260T1 (sl) | Kristalinična (2S,4R)-5-(5'-kloro-2-fluoro-(1,1'-bifenil)-4-il)-2- (etoksimetil)-4-(3-hidroksiizoksazol-5-karboksamido)-2-metilpentanojska kislina in uporaba le-te | |
| MX359110B (es) | Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek. | |
| JP2015536957A5 (enExample) | ||
| EP3233824A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
| MX2016008815A (es) | Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de celulas renales (rcc). | |
| EP3157908A4 (en) | Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole | |
| EP4260910A3 (en) | Pharmaceutical preparation | |
| EP3233079A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
| HK1232884A1 (en) | Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole | |
| PL395738A1 (pl) | Nowe zastosowanie medyczne substancji 4-(n-butylo)-5-(3-chlorofenylo)-2,4-dihydro-3H-1,2,4-triazolo-3-tionu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181002 |